Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

by Strosberg, Jonathan , El-Haddad, Ghassan , Caplin, Martyn , Seregni, Ettore , Ruszniewski, Philippe , Lebtahi, Rachida , Reed, Nicholas , Thevenet, Thomas , Wolin, Edward , Lopera Sierra, Maribel , Baum, Richard P , Yao, James , Mittra, Erik , Krenning, Eric , Hobday, Timothy , Kulkarni, Harshad R , Pavel, Marianne , Öberg, Kjell , Kwekkeboom, Dik , Hendifar, Andrew , Chasen, Beth , Kulke, Matthew H , Mora, Jaime , Van Cutsem, Eric , O’Dorisio, Thomas M , Jacene, Heather , Delpassand, Ebrahim , Bushnell, David , Berlin, Jordan , Kunz, Pamela L , Benson, Al , Srirajaskanthan, Rajaventhan , Erion, Jack L , Santoro, Paola , Grande, Enrique

in Cancer / Cancer therapies / Clinical trials / Disease progression / Intravenous administration / Lymphopenia / Metastases / Metastasis / Midgut / Myelosuppression / Neuroendocrine tumors / Neutropenia / Octreotide / Patients / Somatostatin / Survival / Thrombocytopenia / Tumors

2017

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

2017

Confirm

Do you wish to request the book?

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

2017

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, Jonathan,

El-Haddad, Ghassan,

Caplin, Martyn,

Seregni, Ettore,

Ruszniewski, Philippe,

Lebtahi, Rachida,

Reed, Nicholas,

Thevenet, Thomas,

Wolin, Edward,

Lopera Sierra, Maribel,

Baum, Richard P,

Yao, James,

Mittra, Erik,

Krenning, Eric,

Hobday, Timothy,

Kulkarni, Harshad R,

Pavel, Marianne,

Öberg, Kjell,

Kwekkeboom, Dik,

Hendifar, Andrew,

Chasen, Beth,

Kulke, Matthew H,

Mora, Jaime,

Van Cutsem, Eric,

O’Dorisio, Thomas M,

Jacene, Heather,

Delpassand, Ebrahim,

Bushnell, David,

Berlin, Jordan,

Kunz, Pamela L,

Benson, Al,

Srirajaskanthan, Rajaventhan,

Erion, Jack L,

Santoro, Paola,

Grande, Enrique

2017

Overview

In patients with midgut neuroendocrine tumors that progressed during octreotide analogue therapy, the addition of 177 Lu-Dotatate to octreotide resulted in an 18% response rate and a significantly higher rate of progression-free survival at 20 months than high-dose octreotide alone. Neuroendocrine tumors of the midgut (which is defined as the jejunoileum and the proximal colon) commonly metastasize to the mesentery, peritoneum, and liver and are frequently associated with the carcinoid syndrome. 1 , 2 Neuroendocrine tumors of the midgut represent the most common type of malignant gastrointestinal neuroendocrine tumors and are associated with 5-year survival rates of less than 50% among persons with metastatic disease. 3 , 4 First-line systemic therapy usually consists of a somatostatin analogue for control of both hormonal secretion and tumor growth. 5 – 7 With the exception of everolimus for the treatment of nonfunctional neuroendocrine tumors, 8 no standard second-line systemic treatment . . .

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Cancer

/ Cancer therapies

/ Clinical trials

/ Disease progression

/ Intravenous administration

/ Lymphopenia

/ Metastases